Activitas Nervosa Superior
March 1, 2014
Steven Best
5 citations
Abstract By combining transcranial magnetic stimulation (TMS) with intravenous ketamine therapy, we sought to increase the therapeutic value of TMS and, at the same time, to improve the efficacy of intravenous ketamine therapy among depressed patients previously classified as non-responders. In this preliminary report, we provide evidence for a new and much more reliable method of treating...
Psychiatria Polska
February 20, 2014
Paweł Gosek, Magdalena Chojnacka, Łukasz Święcicki et al.
Cel: W ostatnich latach opublikowano wiele opisów dotyczących możliwości uzyskania szybkiej i istotnej klinicznie poprawy stanu psychicznego u pacjentów z rozpoznaniem depresji po podaniu antagonisty receptorów N-metylo-D-asparaginowych (NMDA) - ketaminy. Większość badań dotyczy podania ketaminy pacjentom z depresją lekooporną, co jednak nie oznaczało oporności na leczenie elektrowstrząsowe. W...
Journal of Affective Disorders
February 18, 2014
D. Luckenbaugh, Mark J. Niciu, Dawn F. Ionescu et al.
282 citations
Background The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in major depression. Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy. Methods Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder...
Research in Neurology An International Journal
February 3, 2014
Botros B. Shenoda
4 citations
The noncompetitive NMDA receptor blocker ketamine provides significant improvement to patients suffering from depression but its mechanistic pathways are not fully understood.The endogenous opioid system is known to be dysregulated in patients with depression.Ketamine is known to interact with the opioid system either directly or indirectly through the release of endogenous opioids.In this...
Drug and Alcohol Dependence
January 15, 2014
Elias Dakwar, C. Anerella, Carl L. Hart et al.
125 citations
Background Sub-anesthetic ketamine infusions may benefit a variety of psychiatric disorders, including addiction. Though ketamine engenders transient alterations in consciousness, it is not known whether these alterations influence efficacy. This analysis evaluates the mystical-type effects of ketamine, which may have therapeutic potential according to prior research, and assesses whether these...
The Annual Review of Pharmacology and Toxicology
January 6, 2014
Mark J. Niciu, Ioline D. Henter, David A. Luckenbaugh et al.
166 citations
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar depression. These effects are in direct contrast to the more modest effects seen after weeks of treatment with classic monoaminergic antidepressants. Numerous open-label and case studies similarly validate ketamine's antidepressant...
The International Journal of Psychiatry in Medicine
2014
M L Zuccoli, A Muscella, C Fucile et al.
Ketamine is an anaesthetic and analgesic drug synthesized in the 1960s from phencyclidine. The recreational use of ketamine increased among the dance culture of techno and house music, in particular in clubs, discotheques, and rave parties. The psychotropic effects of ketamine are now well known and they range from dissociation to positive, negative, and cognitive schizophrenia-like symptoms....
Translational Psychiatry
December 1, 2013
Anne Schmechtig, J. Lees, A. Perkins et al.
The non-competitive N-methyl-D-aspartate receptor antagonist ketamine leads to transient psychosis-like symptoms and impairments in oculomotor performance in healthy volunteers. This study examined whether the adverse effects of ketamine on oculomotor performance can be reversed by the atypical antipsychotic risperidone. In this randomized double-blind, placebo-controlled study, 72 healthy...
Neuropsychopharmacology
December 2013
Shigeyuki Yamamoto, Hiroyuki Ohba, Shingo Nishiyama et al.
Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys underwent four...
Journal of Psychopharmacology
November 20, 2013
Joel Frohlich, John D Van Horn
310 citations
The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizophrenia. The glutamate hypothesis can explain negative and cognitive symptoms of schizophrenia better than the...